StreetInsider.com News Articles

Editas Medicine to present LNP research at ESGCT congress in October

Wed, 14 Oct 2026 09:01:28 -0400

Editas Medicine, Inc. (Nasdaq: EDIT) will present two posters at the European Society of Gene and Cell Therapy 33rd Annual Congress, scheduled for Oct. 27-30, 2026, in Hamburg, Germany, according to a company statement.

Both presentations are scheduled for Oct. 28, 2026, during Poster Session 1, from 1:30 to 3:30 p.m. CET, and will be delivered by Harry An, Director of Process Development at Editas Medicine.

The first poster, abstract number P0361, is titled "Novel targeted LNP delivery achieved in vivo CAR-T cell generation resulting in therapeutically relevant B-cell depletion." The second poster, abstract number P0781, is titled "Development of a configurable,

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

Wed, 14 Oct 2026 09:00:00 -0400

CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33^rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany.

European Society of Gene and Cell Therapy (ESGCT) Congress
Title: Novel targeted LNP delivery achieved in vivo CAR-T cell generation resulting in therapeutically relevant B-cell depletion
Session Date and Time: Wednesday, October 28, 2026, 1:30 - 3:30 p.m. CET
Session Title: Poster

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

Wed, 14 Oct 2026 09:00:00 -0400

European Society of Gene and Cell Therapy (ESGCT) Congress
Title: Novel targeted LNP delivery achieved in vivo CAR-T cell generation resulting in therapeutically relevant B-cell depletion
Session Date and Time: Wednesday, October 28, 2026, 1:30 - 3:30 p.m. CET
Session Title: Poster

Wells Fargo Upgrades Editas Medicine (EDIT) to Equal Weight

Thu, 08 Oct 2026 12:19:07 -0400

Wells Fargo analyst Yanan Zhu upgraded Editas Medicine (NASDAQ: EDIT) from Underweight to Equal Weight with a price target of $6.00 (from $4.00).

For an analyst ratings summary and ratings history on Editas Medicine click here. For more ratings news on Editas Medicine click here.

Shares of Editas Medicine closed at $2.75 yesterday.

Form 8-K Editas Medicine, Inc. For: Oct 08

Thu, 08 Oct 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20261008/27163493.html

Editas Medicine clears first-in-human trial of EDIT-401 in Australia

Thu, 08 Oct 2026 07:01:28 -0400

Editas Medicine (Nasdaq: EDIT) announced it has received Human Research Ethics Committee approval and completed the Clinical Trial Notification process with Australia's Therapeutic Goods Administration to initiate a Phase 1/2 clinical trial of EDIT-401, an experimental gene editing therapy targeting LDL cholesterol reduction.

The trial, called Strive, is designed to evaluate the safety, tolerability, and efficacy of a single dose of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH). The company said it has selected five clinical trial sites across Australia and New Zealand. The trial has also been submitted for regulatory review in New Zealand.

Editas said it expects to begin

Editas Medicine clears first-in-human trial of EDIT-401 in Australia

Thu, 08 Oct 2026 07:01:28 -0400

Editas said it expects to begin

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

Thu, 08 Oct 2026 07:00:00 -0400

Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering

Company remains on track to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027

New EDIT-401 preclinical data demonstrating durability of LDL-C reduction to be presented in oral presentation at AHA Scientific Sessions 2026

CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced it has received

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

Thu, 08 Oct 2026 07:00:00 -0400

Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering

Company remains on track to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027

New EDIT-401 preclinical data demonstrating durability of LDL-C reduction to be presented in oral presentation at AHA Scientific Sessions 2026

Guggenheim Upgrades Editas Medicine (EDIT) to Buy

Wed, 23 Sep 2026 06:24:31 -0400

(Updated - September 23, 2026 6:24 AM EDT)

Guggenheim analyst Debjit Chattopadhyay upgraded Editas Medicine (NASDAQ: EDIT) from Neutral to Buy with a price target of $5.00.

The analyst comments "We are updating our model to reflect EDIT-401, which represents a novel approach to gene editing for severe hypercholesterolemia: (1) preclinical data suggests potentially BiC lipid lowering, with LDL-C & ApoB reductions of >90% and >70%, respectively, at a therapeutically relevant dose; (2) -401 is designed to upregulate LDLR expression by generating a large deletion / inversion in the gene's 3'-UTR with dual gRNAs; and (3) the approach is validated by epidemiological

Guggenheim Upgrades Editas Medicine (EDIT) to Buy

Wed, 23 Sep 2026 06:24:31 -0400

(Updated - September 23, 2026 6:24 AM EDT)

Guggenheim analyst Debjit Chattopadhyay upgraded Editas Medicine (NASDAQ: EDIT) from Neutral to Buy with a price target of $5.00.

Guggenheim Upgrades Editas Medicine (EDIT) to Buy

Wed, 23 Sep 2026 06:24:31 -0400

(Updated - September 23, 2026 6:24 AM EDT)

Guggenheim analyst Debjit Chattopadhyay upgraded Editas Medicine (NASDAQ: EDIT) from Neutral to Buy with a price target of $5.00.

Guggenheim Upgrades Editas Medicine (EDIT) to Buy

Wed, 23 Sep 2026 06:24:31 -0400

(Updated - September 23, 2026 6:24 AM EDT)

Guggenheim analyst Debjit Chattopadhyay upgraded Editas Medicine (NASDAQ: EDIT) from Neutral to Buy with a price target of $5.00.

Editas Medicine grants stock options to new chief medical officer

Wed, 09 Sep 2026 09:00:12 -0400

Editas Medicine, Inc. (Nasdaq: EDIT) announced an inducement stock option grant to its newly appointed Chief Medical Officer, Daniel Ory, M.D., according to a company statement.

The Editas Medicine Board of Directors approved a stock option allowing Dr. Ory to purchase up to 950,000 shares of common stock at $3.03 per share, which was the closing price on the date of the grant. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4).

The options vest over four years, with 25% of shares vesting on the 15th day of the month immediately following the first anniversary of Dr. Ory's start date.

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

Wed, 09 Sep 2026 09:00:00 -0400

CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company’s newly appointed Chief Medical Officer, Daniel Ory, M.D. In connection with Dr. Ory’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. Ory as an inducement material to Dr. Ory entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option provides for the purchase of up to 950,000 shares of Editas Medicine

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

Wed, 09 Sep 2026 09:00:00 -0400

Editas Medicine names Dan Ory as chief medical officer

Tue, 08 Sep 2026 07:00:32 -0400

Editas Medicine, Inc. (Nasdaq: EDIT) named Dan Ory, M.D., as chief medical officer, effective Sept. 8, 2026, according to a press release from the Cambridge, Mass.-based gene editing company.

Dr. Ory brings more than 25 years of experience in cardiovascular medicine and genetic medicine development. He will oversee Editas's clinical development strategy and operations, with a focus on advancing EDIT-401, the company's lead in vivo development candidate for hyperlipidemia, toward clinical trials.

Before joining Editas, Dr. Ory served as chief medical officer at Arbor Biotechnologies, where he led clinical development for an in vivo gene editing program. Prior to that role, he

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Tue, 08 Sep 2026 07:00:00 -0400

Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development

Appointment strengthens executive leadership team as Editas advances EDIT-401 toward clinical development

CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced the appointment of Dan Ory, M.D., as Chief Medical Officer, effective today.

With more than 25 years of experience spanning biotechnology leadership, cardiovascular medicine, and the development of genetic medicines, Dr. Ory will

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Tue, 08 Sep 2026 07:00:00 -0400

Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development

Appointment strengthens executive leadership team as Editas advances EDIT-401 toward clinical development

With more than 25 years of experience spanning biotechnology leadership, cardiovascular medicine, and the development of genetic medicines, Dr. Ory will

Editas Medicine to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 09:00:00 -0400

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September:

Wells Fargo Healthcare Conference
Format: Fireside Chat
Date: Tuesday, September 8
Time: 4:30 p.m. ET
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Format: Fireside Chat
Date: Thursday, September 10
Time: 3:55 p.m. ET
Location: New York, NY

To access the live webcast of Editas Medicine’s Fireside

Editas Medicine to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 09:00:00 -0400

Wells Fargo Healthcare Conference
Format: Fireside Chat
Date: Tuesday, September 8
Time: 4:30 p.m. ET
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Format: Fireside Chat
Date: Thursday, September 10
Time: 3:55 p.m. ET
Location: New York, NY

To access the live webcast of Editas Medicine’s Fireside

Ladenburg Thalmann Starts Editas Medicine (EDIT) at Buy

Tue, 18 Aug 2026 06:35:02 -0400

Ladenburg Thalmann initiates coverage on Editas Medicine (NASDAQ: EDIT) with a Buy rating and a price target of $6.00.

For an analyst ratings summary and ratings history on Editas Medicine click here. For more ratings news on Editas Medicine click here.

Shares of Editas Medicine closed at $2.84 yesterday.

Form SCHEDULE 13G Editas Medicine, Inc. Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260814/26933321.html

Form SCHEDULE 13G Editas Medicine, Inc. Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260814/26933321.html

Form 4 Editas Medicine, Inc. For: Aug 06 Filed by: Ellinor Patrick Thomas II

Fri, 07 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260807/26892206.html